Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia Enrolling
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Last Patient Last Visit Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

For more details, click here for the full news release.

Continue

Ocuphire in the News

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Potential Wide Use for Ocuphire’s APX-3330: An Oral Drug to Prevent Diabetic Retinopathy Progression—Results of the Phase 2 ZETA-1 Trial

Mar 23, 2023

MicroCap Rodeo Winter Wonderland Best Ideas 2023 Conference

Feb 22, 2023

Top five refractive surgery items from 2022

Dec 27, 2022

Pipeline update from Ocuphire

Dec 26, 2022

Phentolamine improved distance-corrected near visual acuity

Dec 20, 2022

Treatment of Presbyopia: One of Several Potential Indications for Nyxol

Dec 1, 2022

Ocuphire partners with Viatris for marketing, commercialization of Nyxol eye drop

Nov 19, 2022

Presbyopia Physician November eUpdate

Nov 10, 2022

Ocuphire initiates Global License Agreement for Nyxol eye drops across 3 indications

Nov 8, 2022

Ocuphire reaches license agreement for the development and commercialization of Nyxol

Nov 8, 2022
RSS
  • 1
  • 2
  • 3
  • 4
  • Next »
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use